Clinical aspects and treatments for pediatric inflammatory bowel disease

Area of Science:

• Pediatric Gastroenterology
• Immunology
• Genetics

Background:

• Global incidence of pediatric inflammatory bowel disease (IBD) is increasing, particularly in developing nations.
• Pediatric IBD exhibits distinct clinical features, including genetic predispositions in monogenic forms, and often presents with more severe inflammation and extensive lesions compared to adult IBD.
• Advanced therapies like anti-tumor necrosis factor α agents have shown efficacy in managing pediatric IBD.

Purpose of the Study:

• To review the current understanding of pediatric inflammatory bowel disease (IBD).
• To highlight the potential benefits of early biologic interventions for high-risk pediatric IBD patients.
• To emphasize the need for developing risk stratification tools for biologic therapy in pediatric IBD.

Main Methods:

• Literature review of recent studies on pediatric IBD.
• Analysis of clinical manifestations and genetic factors in pediatric IBD.
• Evaluation of the role of biologics and anti-tumor necrosis factor α agents.

Main Results:

• Pediatric IBD shows increased incidence and distinct characteristics from adult disease.
• Early use of biologics may be advantageous for pediatric patients with identified high-risk factors.
• Current treatment strategies aim to balance symptom control, growth optimization, and quality of life while minimizing toxicity.

Conclusions:

• Further research is essential to develop precise tools for risk stratification in pediatric IBD.
• Optimizing biologic therapy requires a better understanding of individual patient risk factors.
• The goal is to personalize treatment for improved outcomes and reduced drug toxicity in children with IBD.